Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 16 resultat
Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates generally to biology and medicine and more particularly to methods for treating obesity and obesity-related disorders.
BACKGROUND
Obesity is now a deadly global pandemic. The prevalence of overweight plus obesity among adults in USA in 2008 was
Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at
Kv1.3 potassium channel antagonists
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
This application is a U.S. National Phase Application under 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/EP2015/060073, filed May 7, 2015, and claims priority to Great Britain Application No. 1408135.0, filed May 8, 2014, each of
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
This invention relates to the fields of pharmaceutical and organic chemistry. Embodiments of the present invention relate to, and provide spiro azepane-oxazolidinones(1-oxa-3,8-diazaspiro-[4.6]undecan-2-ones) as voltage gated Kv1.3 potassium channel blockers, and intermediates,
Agent for preventing or ameliorating obesity
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to an agent for preventing or ameliorating obesity, to an agent for inhibiting accumulation of visceral fat, to an agent for inhibiting accumulation of liver lipid, and to an agent for preventing or ameliorating fatty liver.
BACKGROUND OF THE
Dietary supplement and dietary methods employing said supplement for the treatment of obesity
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
In the Specification of my copending Application Ser. No. 338,257 (U.S. Pat. No. 4,009,265), there is described and claimed a method for the treatment of obesity in man, which comprises the steps of giving the overweight patient a daily diet consisting essentially of,
(a)
Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to methods of identification of the sulfonylurea receptor in human adipocytes and other adipocyte-selective calcium channels and calcium mobilization antagonists and use of these factors for treatment of obesity, diabetes, and insulin-resistance related
Dysfunctional satiety center syndrome and method of treatment therefor
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates generally to formulations for assisting in weight control in mammals, for example humans, and more particularly to such a formulation that is a composition containing measured proportions of a plurality of vitamins and minerals.
BACKGROUND OF THE
Combination therapeutic compositions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
In general, the present invention relates to pharmaceutical compositions, and more particularly, to pharmaceutical compositions for the treatment of diabetes mellitus using combination therapy.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a term generally used to refer to
Combination therapeutic compositions and method of use
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
In general, the present invention relates to pharmaceutical compositions, and more particularly, to pharmaceutical compositions for the treatment of diabetes mellitus using combination therapy.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a term generally used to refer to
Combination therapeutic compositions and method of use
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
In general, the present invention relates to pharmaceutical compositions, and more particularly, to pharmaceutical compositions for the treatment of diabetes mellitus using combination therapy.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a term generally used to refer to
Controlled- or delayed-release forms of topiramate
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. TOPIRAMATE
Topiramate is a
Topiramate salts and compositions comprising and methods of making and using the same
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. Topiramate
Topiramate is a
Topiramate sodium trihydrate
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. Topiramate
Topiramate is a
Slim and aqua concentrate having standardized and triple salt stabilized (-)-Hydroxycitric acid from Garcinia cambogia extract for making concentrate and slimming water and their derived product for weight management
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a slim and aqueous extract of Garcinia cambogia standardized to (-)-Hydroxycitric acid ((-)-HCA) as dietary product for weight management. The aqueous extract is further stabilized with triple salt of calcium, magnesium and potassium,
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
